219 related articles for article (PubMed ID: 36759492)
1. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
Kollipara S; Bhattiprolu AK; Boddu R; Ahmed T; Chachad S
AAPS PharmSciTech; 2023 Feb; 24(2):59. PubMed ID: 36759492
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
[TBL] [Abstract][Full Text] [Related]
3. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
[TBL] [Abstract][Full Text] [Related]
4. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.
Kollipara S; Martins FS; Sanghavi M; Santos GML; Saini A; Ahmed T
J Pharm Sci; 2024 Feb; 113(2):345-358. PubMed ID: 38043684
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
[TBL] [Abstract][Full Text] [Related]
6. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
7. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
[TBL] [Abstract][Full Text] [Related]
9. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
[TBL] [Abstract][Full Text] [Related]
10. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.
Pepin X; Arora S; Borges L; Cano-Vega M; Carducci T; Chatterjee P; Chen G; Cristofoletti R; Dallmann A; Delvadia P; Dressman J; Fotaki N; Gray E; Heimbach T; Holte Ø; Kijima S; Kotzagiorgis E; Lennernäs H; Lindahl A; Loebenberg R; Mackie C; Malamatari M; McAllister M; Mitra A; Moody R; Mudie D; Musuamba Tshinanu F; Polli JE; Rege B; Ren X; Rullo G; Scherholz M; Song I; Stillhart C; Suarez-Sharp S; Tannergren C; Tsakalozou E; Veerasingham S; Wagner C; Seo P
Mol Pharm; 2024 Jun; ():. PubMed ID: 38946085
[TBL] [Abstract][Full Text] [Related]
11. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
Wu D; Li M
Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
[TBL] [Abstract][Full Text] [Related]
12. The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
Anand O; Pepin XJH; Kolhatkar V; Seo P
Pharm Res; 2022 Aug; 39(8):1681-1700. PubMed ID: 35585448
[TBL] [Abstract][Full Text] [Related]
13. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.
Pepin XJH; Hammarberg M; Mattinson A; Moir A
Pharm Res; 2023 Feb; 40(2):387-403. PubMed ID: 36002614
[TBL] [Abstract][Full Text] [Related]
15. Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics - a case study and utility in regulatory justifications.
Boddu R; Kollipara S; Bhattiprolu AK; Ahmed T
Xenobiotica; 2023; 53(10-11):587-602. PubMed ID: 38062540
[TBL] [Abstract][Full Text] [Related]
16. Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
Kourentas A; Gajewska M; Lin W; Dhareshwar SS; Steib-Lauer C; Kulkarni S; Hirsch S; Heimbach T; Mueller-Zsigmondy M
AAPS J; 2023 Feb; 25(1):25. PubMed ID: 36788163
[TBL] [Abstract][Full Text] [Related]
17. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
Aishwarya R; Murthy A; Ahmed T; Chachad S
J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
[TBL] [Abstract][Full Text] [Related]
18. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
Kambayashi A; Dressman JB
J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
[TBL] [Abstract][Full Text] [Related]
19. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
